This session will explore the reasons why non-radiographic axial spondyloarthritis (nr-axSpA) is underdiagnosed and underrecognized in the United States. The session will then provide recommendations for MRI implementation and interpretation for nr-axSpA, leveraging a hypothetical patient case to complement the educational information. Lastly, the session will describe clinical trial outcomes in support of CIMZIA® (certolizumab pegol)—the first and only FDA-approved TNF inhibitor indicated for the treatment of adults with active nr-axSpA with objective signs of inflammation. Developed and offered by UCB, Inc.
Non-CME
